COSETTE: Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion

Sponsor
The Cleveland Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT04731363
Collaborator
(none)
40
1
2
32.7
1.2

Study Details

Study Description

Brief Summary

The principal goal for the study is to examine whether ingestion of a beverage containing artificial sweeteners alters in vitro platelet aggregation.

Because of the increasing number of cardiometabolic diseases, such as diabetes mellitus, in the population, the use of artificial sweeteners to replace free sugars has been gaining popularity. Two popular artificial sweeteners are erythritol and xylitol. Erythritol and xylitol are both naturally occurring polyols found in fruits and vegetables. They are potent artificial sweeteners with a higher sweetening intensity and lower calorie content than table sugar.

Previous research has shown that the higher levels of sugar alcohols, like those used as artificial sweeteners, in the blood are related to a higher risk of cardiovascular complications, like heart attacks and strokes, and death. This may be because higher levels of sugar alcohols in one's blood may increase the activity of platelets, which would then increase the risk of heart attack and stroke. The investigators therefore want to find if consuming a single beverage that contains an artificial sweetener can raise the levels of sugar alcohols in the blood and if it can alter platelet function or aggregation.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: xylitol
  • Dietary Supplement: erythritol
N/A

Detailed Description

The purpose of this study is to examine if drinking a single beverage that contains an artificial sweetener can perceptibly alter the activity of platelets in the body. Platelets are a component of blood that are primarily responsible for helping to stop bleeding and repair damaged blood vessels by grouping together, a process known as aggregation, to form clots.

Artificial sweeteners are popular because they have a lower calorie content than table sugar while still making food and beverages sweet. Their use as a sugar substitute is especially attractive for people with heart disease or diabetes, or for people who are trying to lose weight.

Two popular artificial sweeteners are erythritol and xylitol. Erythritol and xylitol are both naturally occurring polyols, also called sugar alcohols, found in fruits and vegetables. They are potent artificial sweeteners with a higher sweetening intensity and lower calorie content than table sugar.This makes them attractive for the use as sugar substitutes or alternatives, particularly for patients with type 2 diabetes.

Up to now, there is no prospective data available about polyols with respect to their impact on event outcomes in cardiovascular patients, despite their extensive use in the food industry. Moreover, little is known about plasma levels and metabolic changes following food intake of artificial sweeteners, in particular polyols.

The investigators have previously measured fasting levels of various polyols in a large clinical cohort of cardiovascular patients and found that some candidate polyols are related to a higher risk of cardiovascular complications and death. In vitro data using human platelets revealed that the polyols xylitol and erythritol at the levels observed in fasting patients induce platelet aggregation potential. The investigator's data shows that erythritol and xylitol impact platelet function and may, therefore, contribute to cardiovascular mortality.

In preliminary studies the investigators found that when ingesting either erythritol or xylitol, the levels of these sweeteners in the plasma rise within the first hour after consumption. With this study the investigators wish to examine whether the postprandial levels are capable of altering platelet function in vitro. The investigators hypothesize that postprandial polyol concentrations following ingestion increase platelet aggregation in the blood.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion
Actual Study Start Date :
Mar 10, 2021
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Xylitol

oral xylitol, a potent artificial sweetener

Dietary Supplement: xylitol
Intervention is a drink consisting of 300mL of water containing 30g of xylitol as a single oral dose.

Experimental: Erythritol

oral erythritol, a potent artificial sweetener

Dietary Supplement: erythritol
Intervention is a drink consisting of 300mL of water containing 30g of erythritol as a single oral dose.

Outcome Measures

Primary Outcome Measures

  1. Platelet Aggregation After Polyol Ingestion [30 minutes]

    Measuring platelet function 30 minutes after polyol ingestion, using established in vitro platelet assays.

  2. Change from Baseline in Platelet Aggregation at 30 minutes Post Polyol Ingestion [Baseline and 30 minutes post ingestion of polyol intervention]

    Measuring changes in platelet function before versus after xylitol or erythritol ingestion, using established in vitro platelet assays.

  3. Plasma Polyol Levels After Polyol Ingestion [30 minutes]

    Measuring plasma levels of polyols 30 minutes after xylitol or erythritol ingestion, using established techniques by mass spectrometry.

  4. Change from Baseline in Plasma Polyol levels at 30 minutes Post Polyol Ingestion [Baseline and 30 minutes post ingestion of polyol intervention]

    Measuring changes in levels of plasma polyols before versus after xylitol or erythritol ingestion, using established techniques by mass spectrometry.

  5. Urinary Polyol levels After Polyol Ingestion [30 minutes]

    Measuring the plasma levels of polyols 30 minutes after xylitol or erythritol ingestion, using established techniques by mass spectrometry.

  6. Change from Baseline in Urinary Polyol Levels at 30 minutes Post Polyol Ingestion [Baseline and 30 minutes post ingestion of polyol intervention]

    Measuring changes in levels of urinary polyols before versus after xylitol or erythritol ingestion, using established techniques by mass spectrometry.

Secondary Outcome Measures

  1. Change from Baseline in Plasma Lipid Profile at 30 minutes Post Polyol Ingestion [Baseline and 30 minutes post ingestion of polyol intervention]

    Measuring changes in lipid levels as markers of changes in metabolism before versus after xylitol or erythritol ingestion.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 18 years or above.

  • Willing and able to sign the consent form.

Exclusion Criteria:
  • Use of anti-platelet medications within 14 days of study enrollment.

  • Active infection or received antibiotics within 1 month of study enrollment.

  • Use of OTC probiotic within 1 month of study enrollment.

  • Diabetes mellitus

  • Ulcerative colitis, Crohn's disease, or other chronic gastrointestinal disorder.

  • Past history of bariatric procedures or surgeries (e.g. gastric banding or bypass).

  • Pregnancy.

  • Significant chronic illness.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cleveland Clinic Cleveland Ohio United States 44195

Sponsors and Collaborators

  • The Cleveland Clinic

Investigators

  • Principal Investigator: Wilson Tang, MD, The Cleveland Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Wilson Tang, Staff, Cellular and Molecular Medicine & Cardiovascular Medicine, Section of Heart Failure, The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT04731363
Other Study ID Numbers:
  • 21-005
First Posted:
Feb 1, 2021
Last Update Posted:
May 6, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wilson Tang, Staff, Cellular and Molecular Medicine & Cardiovascular Medicine, Section of Heart Failure, The Cleveland Clinic
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2022